1
|
Henderson Berg MH, Popradi G, Roberge D, Petrogiannis-Haliotis T, Pehr K. Psychological Distress and Treatment Outcome in Patients With Early-Stage Mycosis Fungoides. J Cutan Med Surg 2024; 28:29-32. [PMID: 38229268 PMCID: PMC10908191 DOI: 10.1177/12034754231220913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2024]
Abstract
BACKGROUND Skin diseases have been shown to worsen psychological distress, which, in turn, may be detrimental to treatment outcomes. Both the impact of psychological distress on response to treatment in mycosis fungoides (MF) and the effect of treatments on psychological well-being are unclear. OBJECTIVES To evaluate (1) the association between pretreatment psychological morbidity and treatment outcome in early-stage MF and (2) the impact of response to treatment on psychological well-being. METHODS This was a prospective cohort study of patients with early-stage MF who started a new stage-directed treatment for their disease. The response was determined using the modified severity-weighted assessment tool, and psychological distress was assessed using the 12-item General Health Questionnaire (GHQ-12) and Penn State Worry Questionnaire (PSWQ). Participants were followed for 1 year. RESULTS In all, 24 consecutive patients were recruited. Objective response rate was 71% (17/24), consistent with existing literature. Prior to treatment, 9 patients (38%) had clinically significant psychological distress on the GHQ-12, while 8 (33%) demonstrated high-level worry on the PSWQ. Of these patients, 6 had pathologic scores on both instruments. Patients with significantly less baseline anxiety/depression on the GHQ-12 responded better to treatment than patients with higher levels (P = .004). In addition, responders' mean GHQ-12 scores decreased by 39% and their PSWQ scores by 17%, whereas nonresponders' GHQ-12 scores increased by 93% (P = .042) and their PSWQ scores by 11% (P = .019). CONCLUSIONS These findings suggest that (1) baseline psychological distress is associated with worse outcomes in patients with early-stage MF and that (2) effective treatment improves psychological morbidity.
Collapse
Affiliation(s)
- Meagan-Helen Henderson Berg
- Division of Dermatology, McGill University, Montréal, QC, Canada
- Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
| | - Gizelle Popradi
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
- Division of Hematology, McGill University, Montréal, QC, Canada
| | - David Roberge
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
- Division of Radiation Oncology, Centre Hospitalier de l’Universite de Montreal, Montréal, QC, Canada
| | - Tina Petrogiannis-Haliotis
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
- Department of Pathology, Jewish General Hospital, McGill University, Montréal, QC, Canada
- Division of Hematology, Department of Medicine, Sir Mortimer B. Davis Jewish General Hospital, Montréal, QC, Canada
| | - Kevin Pehr
- Division of Dermatology, McGill University, Montréal, QC, Canada
- Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
| |
Collapse
|
2
|
Le-Nguyen A, Rys RN, Petrogiannis-Haliotis T, Johnson NA. Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma. Cancer Rep (Hoboken) 2021; 5:e1432. [PMID: 34047076 PMCID: PMC8789614 DOI: 10.1002/cnr2.1432] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Revised: 03/28/2021] [Accepted: 05/05/2021] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND Classical Hodgkin lymphoma (cHL) is one of the most frequently diagnosed neoplasms in young adults and is curable even in the relapse setting. Many patients seek advice regarding pregnancy once they have a sustained complete remission (CR). PD1 inhibitors are effective in inducing CRs in relapsed cHL, but little is known about their effects on pregnancy, fetal outcomes, or risk of relapse. The PD1/PDL1 axis is vital in the maintenance of pregnancy, allowing for fetal tolerance. This axis is also a key pathway by which Hodgkin Reed Sternberg cells escape immune surveillance. Thus, exposure to PD1 inhibitors in the context of a pregnant cHL survivor could potentially lead to maternal and fetal complications as well as increase the risk of relapse. Pregnancy and fetal outcomes following PD1 inhibitors have been reported in women with melanoma, but not cHL. Such data may help physicians counsel their patients on this topic. CASE This case describes a 25-year-old woman who was diagnosed with advanced stage cHL that was treated with multiple courses of chemotherapy and autologous stem cell transplant (ASCT) for primary refractory disease. She experienced a relapse eight months following ASCT and was treated with the PD1 inhibitor pembrolizumab. She completed a total of 21 cycles, achieving a CR after cycle five. After 2 years of sustained CR off pembrolizumab, she had an unassisted and uneventful pregnancy. She delivered a healthy baby boy with no significant complications. He reached his normal milestones in his first year. She remains in CR four years following her last dose of pembrolizumab, evoking the possibility of her being cured of cHL. CONCLUSION Successful pregnancies and fetal outcomes, while maintaining clinical remissions, are possible in women with relapsed cHL treated with pembrolizumab.
Collapse
Affiliation(s)
| | - Ryan N Rys
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Tina Petrogiannis-Haliotis
- Department of Medicine, McGill University, Montreal, Quebec, Canada.,Department of Pathology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - Nathalie A Johnson
- Department of Medicine, McGill University, Montreal, Quebec, Canada.,Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| |
Collapse
|
3
|
Bienz MN, Petrogiannis-Haliotis T, Pehr K, Benlimame N, Mai S, Knecht H. Three-Dimensional Telomeric Fingerprint of Mycosis Fungoides and/or Sézary Syndrome: A Pilot Study. J Invest Dermatol 2020; 141:1598-1601.e4. [PMID: 33212153 DOI: 10.1016/j.jid.2020.09.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 08/29/2020] [Accepted: 09/10/2020] [Indexed: 10/23/2022]
Affiliation(s)
- Marc N Bienz
- Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | | | - Kevin Pehr
- Division of Dermatology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - Naciba Benlimame
- Department of Pathology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - Sabine Mai
- Cell Biology, Research Institute for Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Hans Knecht
- Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
| |
Collapse
|
4
|
Meti N, Petrogiannis-Haliotis T, Esfahani K. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression. J Oncol Pract 2018; 14:514-516. [DOI: 10.1200/jop.18.00177] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Nicholas Meti
- Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | | | | |
Collapse
|
5
|
Wever CM, Geoffrion D, Grande BM, Yu S, Alcaide M, Lemaire M, Riazalhosseini Y, Hébert J, Gavino C, Vinh DC, Petrogiannis-Haliotis T, Dmitrienko S, Mann KK, Morin RD, Johnson NA. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. Leuk Lymphoma 2018; 59:2159-2174. [PMID: 29295643 DOI: 10.1080/10428194.2017.1413186] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Relapse occurs in 10-40% of Burkitt lymphoma (BL) patients that have completed intensive chemotherapy regimens and is typically fatal. While treatment-naive BL has been characterized, the genomic landscape of BL at the time of relapse (rBL) has never been reported. Here, we present a genomic characterization of two rBL patients. The diagnostic samples had mutations common in BL, including MYC and CCND3. Additional mutations were detected at relapse, affecting important pathways such as NFκB (IKBKB) and MEK/ERK (NRAS) signaling, glutamine metabolism (SIRT4), and RNA processing (ZFP36L2). Genes implicated in drug resistance were also mutated at relapse (TP53, BAX, ALDH3A1, APAF1, FANCI). This concurrent genomic profiling of samples obtained at diagnosis and relapse has revealed mutations not previously reported in this disease. The patient-derived cell lines will be made available and, along with their detailed genetics, will be a valuable resource to examine the role of specific mutations in therapeutic resistance.
Collapse
Affiliation(s)
- Claudia M Wever
- a Department of Medicine , McGill University, Lady Davis Institute, Jewish General Hospital , Montreal , Canada.,b Lady Davis Institute, Jewish General Hospital , Montreal , Canada
| | | | - Bruno M Grande
- c Department of Molecular Biology and Biochemistry , Simon Fraser University , Burnaby , Canada.,d Genome Sciences Centre, BC Cancer Agency , Vancouver , Canada
| | - Stephen Yu
- c Department of Molecular Biology and Biochemistry , Simon Fraser University , Burnaby , Canada
| | - Miguel Alcaide
- c Department of Molecular Biology and Biochemistry , Simon Fraser University , Burnaby , Canada
| | - Maryse Lemaire
- b Lady Davis Institute, Jewish General Hospital , Montreal , Canada
| | - Yasser Riazalhosseini
- e Department of Human Genetics , McGill University , Montreal , Canada.,f McGill University and Genome Quebec Innovation Centre , Montreal , Canada
| | - Josée Hébert
- g Department of Medicine, Faculty of Medicine , Université de Montréal , Montreal , Canada.,h Research Centre and Division of Hematology-Oncology Maisonneuve-Rosemont Hospital , The Québec Leukemia Cell Bank , Montreal , Canada
| | - Christina Gavino
- i Infectious Disease Susceptibility Program (Research Institute-McGill University Health Centre) , Montreal , Canada.,j Department of Medicine , Medical Microbiology and Human Genetics (McGill University Health Centre) , Montreal , Canada
| | - Donald C Vinh
- i Infectious Disease Susceptibility Program (Research Institute-McGill University Health Centre) , Montreal , Canada.,j Department of Medicine , Medical Microbiology and Human Genetics (McGill University Health Centre) , Montreal , Canada
| | | | | | - Koren K Mann
- a Department of Medicine , McGill University, Lady Davis Institute, Jewish General Hospital , Montreal , Canada.,b Lady Davis Institute, Jewish General Hospital , Montreal , Canada
| | - Ryan D Morin
- c Department of Molecular Biology and Biochemistry , Simon Fraser University , Burnaby , Canada.,d Genome Sciences Centre, BC Cancer Agency , Vancouver , Canada
| | - Nathalie A Johnson
- a Department of Medicine , McGill University, Lady Davis Institute, Jewish General Hospital , Montreal , Canada.,b Lady Davis Institute, Jewish General Hospital , Montreal , Canada
| |
Collapse
|
6
|
Nikonova A, Esfahani K, Chausse G, Probst S, Petrogiannis-Haliotis T, Knecht H, Gyger G. Erdheim-Chester Disease: The Importance of Information Integration. Case Rep Oncol 2017; 10:613-619. [PMID: 28868020 PMCID: PMC5567069 DOI: 10.1159/000477658] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Accepted: 05/22/2017] [Indexed: 12/24/2022] Open
Abstract
Background Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis disorder that utilizes the RAS-RAF-MEK-ERK pathway. It has a highly variable clinical presentation, where virtually any organ can be involved, thus having the potential of posing a great diagnostic challenge. Over half of the reported cases have the BRAF V600E mutation and have shown a remarkable response to vemurafenib. Case Presentation We describe herein a patient with a history of stroke-like symptoms and retroperitoneal fibrosis that on initial pathology raised the possibility of IgG4-related disease. However, the patient was refractory to high-dose steroids and progressed further, developing an epicardial soft tissue mass and recurrent neurological symptoms. Integration of the above findings with new information at another hospital about a radiological history of symmetrical lower extremities long bone lesions raised the differential diagnosis of ECD. Molecular analysis of formalin-fixed paraffin-embedded tissue of both of the patient's retroperitoneal biopsies (the second one of which had shown a small focus of foamy histiocytes, CD68+/CD1a–) was positive for BRAF mutation, confirming the diagnosis of ECD. The patient demonstrated a dramatic and sustained metabolic response to vemurafenib on follow-up positron emission tomography scans. Conclusion This case highlights the need for developing a high index of suspicion for presentations of retroperitoneal fibrosis that could represent IgG4-related disease but fail to respond to steroids. When unusual multisystem involvement occurs, one should consider a diagnosis of a rare histiocytosis. Vemurafenib appears to be an effective treatment for even advanced cases of both ECD and Langerhans histiocytosis bearing the BRAF V600E mutation.
Collapse
Affiliation(s)
- Anna Nikonova
- McGill University, Jewish General Hospital, Division of Hematology, Department of Medicine, Montreal, QC, Canada
| | - Khashayar Esfahani
- McGill University, Jewish General Hospital, Division of Hematology, Department of Medicine, Montreal, QC, Canada
| | - Guillaume Chausse
- McGill University, Jewish General Hospital, Department of Nuclear Medicine, Montreal, QC, Canada
| | - Stephan Probst
- McGill University, Jewish General Hospital, Department of Nuclear Medicine, Montreal, QC, Canada
| | - Tina Petrogiannis-Haliotis
- McGill University, Jewish General Hospital, Division of Hematology, Department of Medicine, Montreal, QC, Canada.,McGill University, Jewish General Hospital, Department of Pathology, Montreal, QC, Canada
| | - Hans Knecht
- McGill University, Jewish General Hospital, Division of Hematology, Department of Medicine, Montreal, QC, Canada
| | - Genevieve Gyger
- McGill University, Jewish General Hospital, Division of Rheumatology, Department of Medicine, Montreal, QC, Canada
| |
Collapse
|
7
|
Makis W, Ciarallo A, Petrogiannis-Haliotis T, Rosenberg A, Probst S. Follicular lymphoma transforming into diffuse large B-cell lymphoma in spleen: Simultaneous appearance of both on 18F-FDG PET/CT and histology. Clin Imaging 2017; 43:88-92. [PMID: 28259031 DOI: 10.1016/j.clinimag.2017.02.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2016] [Revised: 01/25/2017] [Accepted: 02/17/2017] [Indexed: 10/20/2022]
Abstract
Low grade lymphoma may transform into a more aggressive lymphoma and this transformation is usually associated with a poor outcome. A 65year old man presented with two metabolically active splenic lesions on a staging [18F] fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT). Histologic evaluation post splenectomy confirmed the presence of two clonally related lymphomas: a follicular lymphoma (FL) and a diffuse large B-cell lymphoma (DLBCL). Molecular genetic studies confirmed that the DLBCL lesions arose from a pre-existing FL. We present the 18F-FDG PET/CT imaging characteristics of both lymphoma types which were simultaneously present in the spleen.
Collapse
Affiliation(s)
- William Makis
- Department of Diagnostic Imaging, Cross Cancer Institute, 11560 University Ave NW, Edmonton, Alberta, T6G 1Z2, Canada.
| | - Anthony Ciarallo
- Department of Nuclear Medicine, MUHC McGill University Health Centre, Glen Site, 1001 Boul Decarie, Montreal, Quebec, H4A 3J1, Canada
| | | | - Arthur Rosenberg
- Department of Pathology, Jewish General Hospital, Montreal, QC, Canada
| | - Stephan Probst
- Department of Nuclear Medicine, Jewish General Hospital, Montreal, QC, Canada
| |
Collapse
|
8
|
Abstract
Although familial aggregation of lymphoproliferative disorders has been described, heredity has not been implicated in the etiology of primary cutaneous B-cell lymphomas (PCBCL). We report herein the first case of 2 young monozygotic twins with PCBCL. The first twin was an 18-year-old woman when she presented with multiple skin nodules on the thorax and head. Histology showed an atypical small B-cell proliferation, consistent with primary cutaneous marginal zone lymphoma (PCMZL). Molecular genetics studies demonstrated B-cell clonality. Seven years later, the second twin developed her first lesion that was histologically similar to that of her twin. She subsequently developed other clinically similar lesions. Histology was consistent with PCMZL and showed B-cell clonality. Occurrence of PCBCL in these monozygotic twins raises the possibility of a genetic risk factor. Further study of such rare cases may offer valuable insights into the molecular basis of the etiology and pathogenesis of this unusual disorder.
Collapse
Affiliation(s)
- Houda Bahig
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
| | - Tina Petrogiannis-Haliotis
- Jewish General Hospital, McGill University, Montréal, QC, Canada.,McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
| | - Kevin L Pehr
- Jewish General Hospital, McGill University, Montréal, QC, Canada.,McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
| | - David Roberge
- Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada .,McGill Multidisciplinary Cutaneous Lymphoma Clinic, Montréal, QC, Canada
| |
Collapse
|
9
|
Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, Grewal J, Yu S, Fornika D, Bushell K, Nielsen TH, Petrogiannis-Haliotis T, Crump M, Tosikyan A, Grande BM, MacDonald D, Rousseau C, Bayat M, Sesques P, Froment R, Albuquerque M, Monczak Y, Oros KK, Greenwood C, Riazalhosseini Y, Arseneault M, Camlioglu E, Constantin A, Pan-Hammarstrom Q, Peng R, Mann KK, Johnson NA. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. Clin Cancer Res 2016; 22:2290-300. [PMID: 26647218 DOI: 10.1158/1078-0432.ccr-15-2123] [Citation(s) in RCA: 161] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2015] [Accepted: 11/17/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of patients, and yet little is known about its biology. EXPERIMENTAL DESIGN Using exome sequencing, we characterized the mutation profiles of 38 rrDLBCL biopsies obtained at the time of progression after immunochemotherapy. To identify genes that may be associated with relapse, we compared the mutation frequency in samples obtained at relapse to an unrelated cohort of 138 diagnostic DLBCLs and separately amplified specific mutations in their matched diagnostic samples to identify clonal expansions. RESULTS On the basis of a higher frequency at relapse and evidence for clonal selection, TP53, FOXO1, MLL3 (KMT2C), CCND3, NFKBIZ, and STAT6 emerged as top candidate genes implicated in therapeutic resistance. We observed individual examples of clonal expansions affecting genes whose mutations had not been previously associated with DLBCL including two regulators of NF-κB: NFKBIE and NFKBIZ We detected mutations that may be affect sensitivity to novel therapeutics, such as MYD88 and CD79B mutations, in 31% and 23% of patients with activated B-cell-type of rrDLBCL, respectively. We also identified recurrent STAT6 mutations affecting D419 in 36% of patients with the germinal center B (GCB) cell rrDLBCL. These were associated with activated JAK/STAT signaling, increased phospho-STAT6 protein expression and increased expression of STAT6 target genes. CONCLUSIONS This work improves our understanding of therapeutic resistance in rrDLBCL and has identified novel therapeutic opportunities especially for the high-risk patients with GCB-type rrDLBCL. Clin Cancer Res; 22(9); 2290-300. ©2015 AACR.
Collapse
Affiliation(s)
- Ryan D Morin
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada. Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Sarit Assouline
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. McGill University, Montreal, Quebec, Canada
| | - Miguel Alcaide
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Arezoo Mohajeri
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | | | - Lauren Chong
- University of British Columbia, Vancouver, British Columbia, Canada
| | - Jasleen Grewal
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Stephen Yu
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Daniel Fornika
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Kevin Bushell
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Torsten Holm Nielsen
- Department of Internal Medicine, Copenhagen University Hospital, Roskilde, Denmark
| | | | - Michael Crump
- Princess Margaret Hospital, Toronto, Ontario, Canada
| | | | - Bruno M Grande
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - David MacDonald
- Department of Medicine, University of Dalhousie, Halifax, Nova Scotia, Canada
| | - Caroline Rousseau
- Quebec Clinical Research Organization in Cancer, Montreal, Quebec, Canada
| | | | - Pierre Sesques
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
| | - Remi Froment
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
| | - Marco Albuquerque
- Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Yury Monczak
- Department of Pathology, Jewish General Hospital, Montreal, Quebec, Canada
| | | | - Celia Greenwood
- Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. Department of Oncology, McGill University, Montreal, Quebec, Canada
| | | | | | - Errol Camlioglu
- Department of Radiology, Jewish General Hospital, Montreal, McGill University, Quebec, Canada
| | - André Constantin
- Department of Radiology, Jewish General Hospital, Montreal, McGill University, Quebec, Canada
| | - Qiang Pan-Hammarstrom
- Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital, Huddinge, Sweden. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
| | - Roujun Peng
- Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital, Huddinge, Sweden. Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
| | - Koren K Mann
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. McGill University, Montreal, Quebec, Canada
| | - Nathalie A Johnson
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. McGill University, Montreal, Quebec, Canada.
| |
Collapse
|
10
|
Besner Morin C, Roberge D, Turchin I, Petrogiannis-Haliotis T, Popradi G, Pehr K. Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma. J Cutan Med Surg 2016; 20:244-8. [PMID: 26742957 DOI: 10.1177/1203475415626686] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Numerous treatments are available for cutaneous T-cell lymphoma (CTCL), including systemic retinoids. Very few data are available on topical retinoids. OBJECTIVES The aim of this study was to evaluate the safety and efficiency of tazarotene as monotherapy for early-stage CTCL. METHODS An open-label, prospective study of tazarotene as monotherapy for stages IA to IIA CTCL was conducted. Index lesions on 10 patients were followed for 6 months on treatment, plus at least 6 months off treatment. RESULTS Six patients (60%) showed complete response (CR). Erythema, scaling, thickness, and lesion area decreased progressively throughout treatment. The mean time to CR was 3.8 months; CR was durable for at least 6 months in 83%. Of the 4 patients (40%) without CR, 2 (20%) had stable disease and 2 (20%) stopped the medication because of local side effects; none showed progression. CONCLUSIONS This is the first Canadian trial providing evidence that topical tazarotene has excellent potential as a monotherapy agent for stages I to IIA CTCL.
Collapse
Affiliation(s)
- Catherine Besner Morin
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada Université de Montréal, Montreal, QC, Canada
| | - David Roberge
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada Université de Montréal, Montreal, QC, Canada McGill University, Montreal, QC, Canada
| | | | - Tina Petrogiannis-Haliotis
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada McGill University, Montreal, QC, Canada
| | - Gizelle Popradi
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada McGill University, Montreal, QC, Canada
| | - Kevin Pehr
- McGill Multidisciplinary Cutaneous Lymphoma Clinic, Jewish General Hospital, McGill University, Montreal, QC, Canada McGill University, Montreal, QC, Canada
| |
Collapse
|
11
|
Nielsen TH, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AM, Oros KK, Krumsiek J, Crump M, Morin RD, Cerchietti L, Johnson NA, Petrogiannis-Haliotis T, Miller WH, Assouline SE, Mann KK. Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials. Cancer Epidemiol Biomarkers Prev 2015; 23:2688-93. [PMID: 25472678 DOI: 10.1158/1055-9965.epi-14-0549] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Increasingly, targeted therapies are being developed to treat malignancies. To define targets, determine mechanisms of response and resistance, and develop biomarkers for the successful investigation of novel therapeutics, high-quality tumor biospecimens are critical. We have developed standard operating procedures (SOPs) to acquire and process serial blood and tumor biopsies from patients with diffuse large B-cell lymphoma enrolled in multicenter clinical trials. These SOPs allow for collection and processing of materials suitable for multiple downstream applications, including immunohistochemistry, cDNA microarrays, exome sequencing, and metabolomics. By standardizing these methods, we control preanalytic variables that ensure high reproducibility of results and facilitate the integration of datasets from such trials. This will facilitate translational research, better treatment selection, and more rapid and efficient development of new drugs. See all the articles in this CEBP Focus section, "Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology."
Collapse
Affiliation(s)
| | - Zuanel Diaz
- Quebec Clinical Research Organization in Cancer, Montreal, Quebec, Canada
| | - Rosa Christodoulopoulos
- Clinical Research Unit, Jewish General Hospital, Montreal, McGill University, Quebec, Canada
| | | | - Samia Qureshi
- Quebec Clinical Research Organization in Cancer, Montreal, Quebec, Canada
| | - Caroline Rousseau
- Quebec Clinical Research Organization in Cancer, Montreal, Quebec, Canada
| | - Naciba Benlimame
- Department of Pathology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - Errol Camlioglu
- Department of Radiology, Jewish General Hospital, Montreal, McGill University, Quebec, Canada
| | - André Marc Constantin
- Department of Radiology, Jewish General Hospital, Montreal, McGill University, Quebec, Canada
| | - Kathleen Klein Oros
- Lady Davis Institute for Medical Research, McGill University, Quebec, Canada
| | - Jan Krumsiek
- Institute of Computational Biology, Helmholtz Zentrum München, Germany. Division of Hematology and Oncology, Department of Medicine, Cornell University, New York, New York
| | - Michael Crump
- Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Ryan D Morin
- Department of Molecular Biology and Biochemistry, Simon Frasier University, Burnaby, British Columbia, Canada
| | - Leandro Cerchietti
- Division of Hematology and Oncology, Department of Medicine, Cornell University, New York, New York
| | - Nathalie A Johnson
- Lady Davis Institute for Medical Research, McGill University, Quebec, Canada. Department of Hematology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. Department of Oncology, McGill University, Quebec, Canada
| | | | - Wilson H Miller
- Lady Davis Institute for Medical Research, McGill University, Quebec, Canada. Department of Oncology, McGill University, Quebec, Canada
| | - Sarit E Assouline
- Lady Davis Institute for Medical Research, McGill University, Quebec, Canada. Department of Hematology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - Koren K Mann
- Lady Davis Institute for Medical Research, McGill University, Quebec, Canada. Department of Oncology, McGill University, Quebec, Canada.
| |
Collapse
|
12
|
Marton A, Kezouh A, Petrogiannis-Haliotis T, Assouline S. Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials. Leuk Lymphoma 2015; 56:2747-9. [DOI: 10.3109/10428194.2015.1010079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
13
|
Varga C, Holcroft C, Kezouh A, Bucatel S, Johnson N, Petrogiannis-Haliotis T, Assouline S. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study. Leuk Lymphoma 2013; 55:533-7. [DOI: 10.3109/10428194.2013.790968] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
14
|
Fernandes BF, Al-Mujaini A, Petrogiannis-Haliotis T, Al-Kandari A, Arthurs B, Burnier MN. Epithelioid hemangioma (angiolymphoid hyperplasia with eosinophilia) of the orbit: a case report. J Med Case Rep 2007; 1:30. [PMID: 17592625 PMCID: PMC1913531 DOI: 10.1186/1752-1947-1-30] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2007] [Accepted: 06/25/2007] [Indexed: 11/23/2022] Open
Abstract
Background Angiolymphoid hyperplasia with eosinophilia (ALHE) and Kimura's Disease (KD) share many clinical and histopathological features. Although they were once considered different stages of the same disease, they are now known to represent separate entities. Recently, ALHE is being called epithelioid hemangioma (EH), a term that better describes the possible neoplastic nature of the entity. Case Presentation An eighteen year-old Asian female presented with a three-month history of fluctuating swelling and ptosis of the left upper eyelid. Computed tomography disclosed a distinct homogeneous lesion in the left superior orbit, molding to the globe and other orbital structures. At histopathological evaluation the lesion was composed of numerous blood vessels lined by plump endothelial cells with oval nuclei protruding into the lumen. Surrounding the vessels, there was a chronic inflammatory infiltrate with a large proportion of eosinophils. Based on clinical and histopathological findings, the diagnosis of EH was made. Conclusion Although exams like blood count, urinalysis and whole body scans can assist in the differential diagnosis, EH can be diagnosed and differentiated from KD on histopathological grounds. The presence of vascular hyperplasia with plump endothelial cells protruding into the lumen is the most important discriminator in establishing the diagnosis of EH. Such distinction is crucial for the patient because EH is not associated with any of the systemic manifestations present in KD.
Collapse
Affiliation(s)
- Bruno F Fernandes
- Department of Ophthalmology and Pathology. Henry C. Witelson Ocular Pathology Laboratory & Mcgill University Health Centre, Montreal, QC, Canada
- Department of Ophthalmology. Federal University of São Paulo, São Paulo, Brazil
| | - Abdullah Al-Mujaini
- Department of Ophthalmology Mcgill University Health Centre. Montreal, QC, Canada
| | | | - Abdullah Al-Kandari
- Department of Ophthalmology and Pathology. Henry C. Witelson Ocular Pathology Laboratory & Mcgill University Health Centre, Montreal, QC, Canada
| | - Bryan Arthurs
- Department of Ophthalmology Mcgill University Health Centre. Montreal, QC, Canada
| | - Miguel N Burnier
- Department of Ophthalmology and Pathology. Henry C. Witelson Ocular Pathology Laboratory & Mcgill University Health Centre, Montreal, QC, Canada
- Department of Ophthalmology. Federal University of São Paulo, São Paulo, Brazil
| |
Collapse
|
15
|
Kempf W, Levi E, Kamarashev J, Kutzner H, Pfeifer W, Petrogiannis-Haliotis T, Burg G, Kadin ME. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol 2002; 29:295-300. [PMID: 12100631 DOI: 10.1034/j.1600-0560.2002.290507.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND CD30-positive cutaneous lymphoproliferative disorders (LPD) represent a spectrum of diseases ranging from low-grade (lymphomatoid papulosis; LyP) to high-grade (pleomorphic and anaplastic large-cell lymphoma; PTL, ALCL) with overlapping morphologic and immunophenotypic features. The common phenotypic hallmark is the expression of CD30-antigen by the tumor cells which morphologically resemble Reed-Sternberg cells. Although LyP is a non-fatal recurring disorder, it is associated with systemic lymphomas including Hodgkin's lymphoma (HL), mycosis fungoides (MF) and ALCL in 5-20% of the cases. Currently there is no marker to predict the development of systemic lymphomas in patients with LyP. Fascin, an actin bundling protein, has recently been shown to be a unique marker found in almost 100% of classical HL. METHODS Because of the association of LyP with HL, fascin expression was analyzed by immunohistochemistry in LyP (n = 45), cutaneous CD30+ ALCL (n = 17) and pleomorphic T-cell lymphoma (n = 9) (PTL) and LyP associated with systemic lymphomas (7 HL, 2 ALCL, 1 MF), with the intent to determine if fascin expression can predict disease progression. RESULTS Fascin was expressed by tumor cells in 11/45 (24%) cases of LyP, 11/17 (64%) cases of ALCL, 7/9 (77%) cases of PTL and 6/10 (60%) cases of LyP associated with systemic lymphomas. Fascin expression in LyP was significantly less frequent than in ALCL (p < 0.001) and also than in LyP associated with lymphomas (p < 0.05). There was no significant difference of fascin expression within the histological subtypes of LyP. We found no evidence of ALK expression nor of Epstein-Barr virus expression in any case either by in situ hybridization or immunohistochemistry in the LyP cases associated with HL. CONCLUSIONS This is the first study to demonstrate that fascin is expressed in cutaneous CD30+ LPD and that it is a candidate marker of disease progression in LyP.
Collapse
Affiliation(s)
- Werner Kempf
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215, USA
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Petrogiannis-Haliotis T, Sakoulas G, Kirby J, Koralnik IJ, Dvorak AM, Monahan-Earley R, DE Girolami PC, DE Girolami U, Upton M, Major EO, Pfister LA, Joseph JT. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med 2001; 345:1250-5. [PMID: 11680445 DOI: 10.1056/nejmoa010319] [Citation(s) in RCA: 101] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- T Petrogiannis-Haliotis
- Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Levi E, Wang Z, Petrogiannis-Haliotis T, Pfeifer WM, Kempf W, Drews R, Kadin ME. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression. J Invest Dermatol 2000; 115:1034-40. [PMID: 11121138 DOI: 10.1046/j.1523-1747.2000.00175.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Lymphomatoid papulosis is part of a spectrum of CD30+ cutaneous lymphoproliferative disorders characterized by spontaneous tumor regression. The mechanism(s) of regression is unknown. In a recent study, a selective increase in CD30 ligand expression in regressing lesions of lymphomatoid papulosis and cutaneous CD30+ anaplastic large cell lymphoma was shown, suggesting that activation of the CD30 signaling pathway may be responsible for tumor regression, whereas no difference in Fas/Fas ligand expression was found between regressing and nonregressing lesions. Therefore we tested the effects of CD30 and Fas activation on three CD30+ cutaneous lymphoma cell lines (Mac-1, Mac-2 A, JK) derived from nonregressing tumors of two patients who had progressed from lymphomatoid papulosis to systemic anaplastic large cell lymphoma. To evaluate the effects of CD30 signaling, the cell lines were incubated with a CD30 agonistic antibody, HeFi-1. Proliferative responses, mitogen-activated protein kinase, and nuclear factor kappa B activities were determined with and without CD30 activation. Mac-1 and Mac-2 A showed increased proliferative responses to incubation with CD30 activating antibody, HeFi-1. Inhibition of the mitogen-activated protein kinase activity caused growth inhibition of the Mac-1, Mac-2 A, and JK cell lines. Activation of the Fas pathway induced apoptosis in all three cell lines. Taken together, these findings suggest that resistance to CD30-mediated growth inhibition provides a possible mechanism for escape of cutaneous anaplastic large cell lymphoma from tumor regression. Mitogen-activated protein kinase inhibitors are potential therapeutic agents for the treatment of advanced cutaneous anaplastic large cell lymphoma. J Invest Dermatol 115:1034-1040, 2000
Collapse
Affiliation(s)
- E Levi
- Department of Pathology, Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Pfeifer W, Levi E, Petrogiannis-Haliotis T, Lehmann L, Wang Z, Kadin ME. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1). Am J Pathol 1999; 155:1353-9. [PMID: 10514417 PMCID: PMC1867013 DOI: 10.1016/s0002-9440(10)65237-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
To develop a model for the biology and treatment of CD30+ anaplastic large cell lymphoma (ALCL), we transplanted leukemic tumor cells from a 22-month-old girl with multiple relapsed ALCL. Tumor cells were inoculated intraperitoneally into a 4-week-old SCID/bg mouse and produced a disseminated tumor within 8 weeks; this tumor was serially transplanted by subcutaneous injections to other mice. Morphology, immunohistochemistry, and molecular genetics which demonstrated the NPM-ALK fusion protein, resulting from the t(2;5)(p23;q35), confirmed the identity of the xenograft with the original tumor. The tumor produced transcripts for interleukin-1alpha, tumor necrosis factor-alpha, and interferon-gamma which could explain the patient's B-symptoms. Treatment of mice with monoclonal antibody (HeFi-1) which activates CD30 antigen administered on day 1 after tumor transplantation prevented tumor growth. Treatment with HeFi-1 after tumors had reached a 0.2 cm(3) volume caused tumor growth arrest and prevention of tumor dissemination. We conclude that transplantation of CD30+ ALCL to SCID/bg mice may provide a valuable model for the study of the biology and design of treatment modalities for CD30+ ALCL.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/therapeutic use
- Biomarkers, Tumor/biosynthesis
- Cell Division/drug effects
- Disease Models, Animal
- Female
- Flow Cytometry
- Gene Expression
- Humans
- Immunohistochemistry
- Immunophenotyping
- Infant
- Ki-1 Antigen/immunology
- Ki-1 Antigen/metabolism
- Lymphoma, Large-Cell, Anaplastic/drug therapy
- Lymphoma, Large-Cell, Anaplastic/genetics
- Lymphoma, Large-Cell, Anaplastic/metabolism
- Lymphoma, Large-Cell, Anaplastic/pathology
- Mice
- Mice, SCID
- Neoplasm Transplantation
- Protein-Tyrosine Kinases/biosynthesis
- Protein-Tyrosine Kinases/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Transplantation, Heterologous
Collapse
Affiliation(s)
- W Pfeifer
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | | | | | |
Collapse
|